ScholarLens Back to search
2012•Unpublished venueRequires access

Dasatinib Achieves Higher Response Rate Than Imatinib in CML

Dave Levitan

Open publisher page 0 citations

Abstract

A study comparing dasatinib to imatinib in patients with chronic myeloid leukemia found that the second-generation TKI dasatinib yielded better remission and molecular response rates than imatinib, but these did not result in better survival outcomes.

About this research paper

What this paper is about

A study comparing dasatinib to imatinib in patients with chronic myeloid leukemia found that the second-generation TKI dasatinib yielded better remission and molecular response rates than imatinib, but these did not result in better survival outcomes.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

A study comparing dasatinib to imatinib in patients with chronic myeloid leukemia found that the second-generation TKI dasatinib yielded better remission and molecular response rates than imatinib, but these did not result in better survival outcomes.

Key concepts: Dasatinib, Imatinib, Myeloid leukemia, Medicine, Internal medicine, Oncology, Imatinib mesylate, Nilotinib

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Dasatinib Achieves Higher Response Rate Than Imatinib in CML — Research Paper | ScholarLens